Oxidative Medicine and Cellular Longevity
Volume 2017 (2017), Article ID 1913954, 1 page
https://doi.org/10.1155/2017/1913954

Corrigendum

Corrigendum to “Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E₂ Receptor EP4 Pathway”

Yu Ah Hong,¹ Keum Jin Yang,² So Young Jung,² Ki Cheol Park,² Hyunsu Choi,² Jeong Min Oh,² Sang Ju Lee,¹ Yoon Kyung Chang,¹ Cheol WheePark,¹ Chul Woo Yang,¹ Suk Young Kim,¹ and Hyeon Seok Hwang¹

¹Division of Nephrology, Department of Internal Medicine, College of Medicine, the Catholic University of Korea, Seoul, Republic of Korea
²Clinical Research Institute, Daejeon St. Mary’s Hospital, Daejeon, Republic of Korea

Correspondence should be addressed to Hyeon Seok Hwang; hwanghs@catholic.ac.kr

Received 6 June 2017; Accepted 2 July 2017; Published 13 August 2017

Copyright © 2017 Yu Ah Hong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E₂ Receptor EP4 Pathway” [1], an acknowledgement should be added as follows:

The authors also wish to acknowledge the financial support of the Korean Society of Nephrology (JW Pharmaceutical, 2013).

References

Y. A. Hong, K. J. Yang, S. Y. Jung et al., “Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E₂ Receptor EP4 Pathway,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 5031926, 17 pages, 2017.